L. Chesnel

发表

Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial

T. Louie, P. Daley, S. Khanna, 2017, The Journal of antimicrobial chemotherapy.

Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes

K. Garey, B. Endres, L. Chesnel, 2016, Antimicrobial Agents and Chemotherapy.

Discovery and development of surotomycin for the treatment of Clostridium difficile

L. Chesnel, Victoria Knight-Connoni, Carmela T. M. Mascio, 2016, Journal of Industrial Microbiology & Biotechnology.

Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection

T. Louie, Kaiyu Wu, L. Chesnel, 2017, The Journal of antimicrobial chemotherapy.

Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection.

M. Wilcox, J. Freeman, S. Nicholson, 2014, The Journal of antimicrobial chemotherapy.

Effect of Fidaxomicin versus Vancomycin on Susceptibility to Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice

C. Donskey, J. Cadnum, A. Deshpande, 2016, Antimicrobial Agents and Chemotherapy.

Impact of Variations in Test Method Parameters on In Vitro Activity of Surotomycin against Clostridium difficile and Surotomycin Quality Control Limits for Broth Microdilution and Agar Dilution Susceptibility Testing

Steven D. Brown, J. Deane, D. Sahm, 2015, Journal of Clinical Microbiology.

Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities

R. P. Ross, C. Hill, B. Healy, 2022, Scientific reports.

Identical Penicillin-Binding Domains in Penicillin-Binding Proteins of Streptococcus pneumoniae Clinical Isolates with Different Levels of β-Lactam Resistance

T. Vernet, O. Dideberg, A. Zapun, 2005, Antimicrobial Agents and Chemotherapy.

Biochemical Characterization of Streptococcus pneumoniae Penicillin-Binding Protein 2b and Its Implication in β-Lactam Resistance

T. Vernet, O. Dideberg, A. D. Di Guilmi, 2004, Antimicrobial Agents and Chemotherapy.

Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities.

R. Goering, S. Sambol, Stuart Johnson, 2020, The Journal of antimicrobial chemotherapy.

Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection

R. Fedorak, K. Mullane, U. Stoutenburgh, 2017, Open forum infectious diseases.

Mode of Action and Bactericidal Properties of Surotomycin against Growing and Nongrowing Clostridium difficile

L. Chesnel, Carmela T. M. Mascio, J. Hurdle, 2015, Antimicrobial Agents and Chemotherapy.

Mode of Action and Bactericidal Properties of Surotomycin against Growing and Nongrowing Clostridium difﬁcile

L. Chesnel, Carmela T. M. Mascio, J. Hurdle, 2015 .

Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015.

D. Gerding, E. Goldstein, S. Sambol, 2018, Anaerobe.

Surotomycin Demonstrates Low In Vitro Frequency of Resistance and Rapid Bactericidal Activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium

L. Chesnel, Carmela T. M. Mascio, J. Silverman, 2014, Antimicrobial Agents and Chemotherapy.

Comparison of Clostridium difficile minimum inhibitory concentrations obtained using agar dilution vs broth microdilution methods.

D. Citron, L. Chesnel, J. Nary, 2017, Anaerobe.

In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agents.

L. Chesnel, C. Jacqueline, K. Howland, 2017, Journal of global antimicrobial resistance.

The Capping Domain in RalF Regulates Effector Functions

J. Cherfils, Aimee M. Tucker, D. Wood, 2012, PLoS Pathogens.

Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial

E. Goldstein, D. Citron, L. Chesnel, 2016, Antimicrobial Agents and Chemotherapy.

ADS024, a Bacillus velezensis strain, protects human colonic epithelial cells against C. difficile toxin-mediated apoptosis

H. Feng, C. Pothoulakis, H. Koon, 2023, Frontiers in Microbiology.

Mutations Associated with Reduced Surotomycin Susceptibility in Clostridium difficile and Enterococcus Species

Hannah M. Adams, Kelli L. Palmer, L. Chesnel, 2015, Antimicrobial Agents and Chemotherapy.

Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice

N. Ajami, J. Petrosino, M. Wong, 2018, Antimicrobial Agents and Chemotherapy.

Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment

P. Stewart, G. James, L. Chesnel, 2018, The Journal of antimicrobial chemotherapy.

A yeast genetic system for the identification and characterization of substrate proteins transferred into host cells by the Legionella pneumophila Dot/Icm system

C. Roy, L. Chesnel, E. Campodonico, 2005, Molecular microbiology.

The Structural Modifications Induced by the M339F Substitution in PBP2x from Streptococcus pneumoniae Further Decreases the Susceptibility to β-Lactams of Resistant Strains*

T. Vernet, O. Dideberg, A. Zapun, 2003, Journal of Biological Chemistry.

Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.

T. Louie, Christine H. Lee, K. Mullane, 2016, The Journal of antimicrobial chemotherapy.

Bactericidal Activity in Clostridium difficile, Enterococcus faecalis and 2

L. Chesnel, Carmela T. M. Mascio, J. Silverman, 2014 .

Pneumococcal β-Lactam Resistance Due to a Conformational Change in Penicillin-binding Protein 2x*

T. Vernet, A. Zapun, R. Carapito, 2006, Journal of Biological Chemistry.

Effect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice

C. Donskey, J. Cadnum, A. Deshpande, 2016, Antimicrobial Agents and Chemotherapy.

A PBP2x from a Clinical Isolate of Streptococcus pneumoniae Exhibits an Alternative Mechanism for Reduction of Susceptibility to β-Lactam Antibiotics*

T. Vernet, O. Dideberg, A. Le Gouellec, 2004, Journal of Biological Chemistry.

Increase of the deacylation rate of PBP2x from Streptococcus pneumoniae by single point mutations mimicking the class A beta-lactamases.

T. Vernet, O. Dideberg, A. Zapun, 2002, European journal of biochemistry.

Effects of Surotomycin on Clostridium difficile Viability and Toxin Production In Vitro

S. Tzipori, D. Schmidt, A. Sonenshein, 2015, Antimicrobial Agents and Chemotherapy.

Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo

M. Rea, L. Chesnel, M. M. O’Donnell, 2023, World journal of gastrointestinal pathophysiology.

1 The structural modifications induced by the M339F substitution in PBP2x from Streptococcus pneumoniae , further decreases the susceptibility to ββββ - lactams of resistant strains.

T. Vernet, O. Dideberg, A. Zapun, 2003 .